| Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma J Krejcik, T Casneuf, IS Nijhof, B Verbist, J Bald, T Plesner, K Syed, K Liu, ... Blood, The Journal of the American Society of Hematology 128 (3), 384-394, 2016 | 1006 | 2016 |
| Modeling gene and genome duplications in eukaryotes S Maere, S De Bodt, J Raes, T Casneuf, M Van Montagu, M Kuiper, ... Proceedings of the National Academy of Sciences 102 (15), 5454-5459, 2005 | 1002 | 2005 |
| CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma IS Nijhof, T Casneuf, J Van Velzen, B van Kessel, AE Axel, K Syed, ... Blood, The Journal of the American Society of Hematology 128 (7), 959-970, 2016 | 404 | 2016 |
| Nonrandom divergence of gene expression following gene and genome duplications in the flowering plant Arabidopsis thaliana T Casneuf, S De Bodt, J Raes, S Maere, Y Van de Peer Genome biology 7, 1-11, 2006 | 203 | 2006 |
| A phase 2 multicentre study of siltuximab, an anti‐interleukin‐6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma PM Voorhees, RF Manges, P Sonneveld, S Jagannath, G Somlo, ... British journal of haematology 161 (3), 357-366, 2013 | 171 | 2013 |
| In situ analysis of cross-hybridisation on microarrays and the inference of expression correlation T Casneuf, Y Van de Peer, W Huber BMC bioinformatics 8, 1-13, 2007 | 118 | 2007 |
| Quantitative RNA expression analysis with Affymetrix Tiling 1.0 R arrays identifies new E2F target genes N Naouar, K Vandepoele, T Lammens, T Casneuf, G Zeller, ... The Plant Journal 57 (1), 184-194, 2009 | 80 | 2009 |
| Identification of novel regulatory modules in dicotyledonous plants using expression data and comparative genomics K Vandepoele, T Casneuf, Y Van de Peer Genome biology 7, 1-15, 2006 | 75 | 2006 |
| IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9 HHH Erb, RV Langlechner, PL Moser, F Handle, T Casneuf, K Verstraeten, ... Endocrine-related cancer 20 (5), 677, 2013 | 66 | 2013 |
| Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer T Casneuf, AE Axel, P King, JD Alvarez, JL Werbeck, T Verhulst, ... Breast Cancer: Targets and Therapy, 13-27, 2016 | 51 | 2016 |
| Efficacy of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients with 1 to 3 prior lines of … SZ Usmani, MA Dimopoulos, A Belch, D White, L Benboubker, G Cook, ... Blood 128 (22), 1151, 2016 | 50 | 2016 |
| Evaluation of minimal residual disease (MRD) in relapsed/refractory multiple myeloma (RRMM) patients treated with daratumumab in combination with lenalidomide plus … H Avet-Loiseau, T Casneuf, C Chiu, JP Laubach, JJ Lee, P Moreau, ... Blood 128 (22), 246, 2016 | 47 | 2016 |
| Daratumumab in combination with lenalidomide plus dexamethasone induces clonality increase and T-cell expansion: results from a phase 3 randomized study (POLLUX) C Chiu, T Casneuf, A Axel, A Lysaght, J Bald, NZ Khokhar, T Plesner, ... Blood 128 (22), 4531, 2016 | 46 | 2016 |
| Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory myeloma based on prior lines of therapy: updated analysis … MV Mateos, J Estell, W Barreto, P Corradini, CK Min, E Medvedova, M Qi, ... Blood 128 (22), 1150, 2016 | 45 | 2016 |
| Daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): updated efficacy and safety … MA Dimopoulos, DJ White, L Benboubker, G Cook, M Leiba, J Morton, ... Blood 130, 739, 2017 | 44 | 2017 |
| Immunomodulatory effects and adaptive immune response to daratumumab in multiple myeloma J Krejcik, T Casneuf, I Nijhof, B Verbist, J Bald, T Plesner, K Liu, ... Blood 126 (23), 3037, 2015 | 43 | 2015 |
| Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX). NJ Bahlis, P Moreau, H Nahi, T Plesner, H Goldschmidt, K Suzuki, ... Journal of Clinical Oncology 35 (15_suppl), 8025-8025, 2017 | 27 | 2017 |
| Daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (CASTOR). S Lentzsch, KC Weisel, MV Mateos, V Hungria, M Munder, AK Nooka, ... Journal of Clinical Oncology 35 (15_suppl), 8036-8036, 2017 | 13 | 2017 |
| High-parameter mass cytometry (CyTOF) evaluation of relapsed/refractory multiple myeloma (MM) Pts (Pts) treated with daratumumab supports immune modulation as a novel mechanism … H Adams III, F Stevenaert, J Krejcik, K Van der Borght, T Casneuf, T Smets, ... Blood 128 (22), 4521, 2016 | 12 | 2016 |
| Daratumumab, bortezomib and dexamethasone versus bortezomib and dexamethasone alone for relapsed or refractory multiple myeloma based on prior treatment exposure: updated … AA Chanan-Khan, S Lentzsch, H Quach, N Horvath, M Capra, R Ovilla, ... Blood 128 (22), 3313, 2016 | 11 | 2016 |
